Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations
Cells · 25.08.2023 · 12 (17) · 2147
DOI: 10.3390/cells12172147 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 25.08.2023. Verfasst von Kyu-Won Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong. Hauptthemen laut MEDLINE: Drug-Related Side Effects and Adverse Reactions, Extracellular Vesicles. Die Arbeit wurde bisher 129-mal zitiert (Crossref) und nennt 397 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: RGC Theme-based Research Scheme.
Abstract (Originalsprache)
In the emerging era of cancer immunotherapy, immune checkpoint blockades (ICBs) and adoptive cell transfer therapies (ACTs) have gained significant attention. However, their therapeutic efficacies are limited due to the presence of cold type tumors, immunosuppressive tumor microenvironment, and immune-related side effects. On the other hand, dendritic cell (DC)-based vaccines have been suggested as a new cancer immunotherapy regimen that can address the limitations encountered by ICBs and ACTs. Despite the success of the first generation of DC-based vaccines, represented by the first FDA-approved DC-based therapeutic cancer vaccine Provenge, several challenges remain unsolved. Therefore, new DC vaccine strategies have been actively investigated. This review addresses the limitations of the currently most adopted classical DC vaccine and evaluates new generations of DC vaccines in detail, including biomaterial-based, immunogenic cell death-inducing, mRNA-pulsed, DC small extracellular vesicle (sEV)-based, and tumor sEV-based DC vaccines. These innovative DC vaccines are envisioned to provide a significant breakthrough in cancer immunotherapy landscape and are expected to be supported by further preclinical and clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.
- State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong.
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao.
ORCID-Profile: Judy Wai Ping Yam
Förderung
- RGC Theme-based Research Scheme
Zitieren
APA
Lee, K. W., Yam, J. W. P., & Mao, X. (2023). Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations. Cells, 12(17), 2147. https://doi.org/10.3390/cells12172147
Vancouver
Lee KW, Yam JWP, Mao X. Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations. Cells. 2023;12(17):2147. doi:10.3390/cells12172147
BibTeX
@article{Lee2023,
author = {Lee, Kyu-Won and Yam, Judy Wai Ping and Mao, Xiaowen},
title = {Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations},
journal = {Cells},
year = {2023},
volume = {12},
number = {17},
pages = {2147},
doi = {10.3390/cells12172147}
}
EUVIMED